Building a Common Language: Boehringer Ingelheim Pharma GmbH & Co. KG on Interaction with Regulatory Bodies

Add bookmark

In this exclusive interview Dr. Torsten Grünewald - Lead Business Architect at Boehringer Ingelheim Pharma GmbH & Co. KG expresses the need for a common language when interacting with regulatory bodies to make information models such as RIM really work. Pharma IQ: What are the major challenges today for effectively managing information for the purpose of regulatory submissions? T Grünewald: Non-integrated processes in the company and the different  requirements p...
To continue reading this story get free access